Kyle A Romine
Overview
Explore the profile of Kyle A Romine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romine K, Bottomly D, Yashar W, Long N, Viehdorfer M, McWeeney S, et al.
Front Oncol
. 2023 Jun;
13:1192829.
PMID: 37361575
Introduction: The implementation of small-molecule and immunotherapies in acute myeloid leukemia (AML) has been challenging due to genetic and epigenetic variability amongst patients. There are many potential mechanisms by which...
2.
Romine K, MacPherson K, Cho H, Kosaka Y, Flynn P, Byrd K, et al.
Leukemia
. 2023 Jan;
37(3):580-592.
PMID: 36681742
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the...
3.
Barnes E, Eide C, Kaempf A, Bottomly D, Romine K, Wilmot B, et al.
Br J Haematol
. 2022 Oct;
200(3):323-328.
PMID: 36264026
Drug resistance in chronic myeloid leukaemia (CML) may occur via mutations in the causative BCR::ABL1 fusion or BCR::ABL1-independent mechanisms. We analysed 48 patients with BCR::ABL1-independent resistance for the presence of...
4.
Bottomly D, Long N, Schultz A, Kurtz S, Tognon C, Johnson K, et al.
Cancer Cell
. 2022 Jul;
40(8):850-864.e9.
PMID: 35868306
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large...
5.
Romine K, van Galen P
Blood Cancer Discov
. 2022 Jun;
3(4):270-272.
PMID: 35709709
Myelodysplastic syndrome (MDS) describes a family of blood disorders driven by the clonal expansion of mutated blood cells that can evolve into secondary acute myeloid leukemia (sAML). Two new studies...
6.
Romine K, Nechiporuk T, Bottomly D, Jeng S, McWeeney S, Kaempf A, et al.
Blood Cancer Discov
. 2021 Sep;
2(5):518-531.
PMID: 34568834
To understand mechanisms of response to BET inhibitors (BETi), we mined the Beat AML functional genomic dataset and performed genome-wide CRISPR screens on BETi- sensitive and BETi- resistant AML cells....
7.
Moshofsky K, Cho H, Wu G, Romine K, Newman M, Kosaka Y, et al.
Blood Adv
. 2019 Oct;
3(20):3038-3051.
PMID: 31648326
Acute myeloid leukemia (AML) remains difficult to treat due to mutational heterogeneity and the development of resistance to therapy. Targeted agents, such as MEK inhibitors, may be incorporated into treatment;...